Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related ENDP
Analyst: Boston Scientific's Acquisition Is 'Strategically Sound'
Benzinga's M&A Chatter for Monday March 2, 2015
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks (Seeking Alpha)
Related FHN
12 Big Banks To Watch Ahead Of The Coming Fed Stress Test
Earnings Scheduled For January 23, 2015

Analysts at Cantor Fitzgerald downgraded Endo Health Solutions (NASDAQ: ENDP) from “hold” to “sell.” The target price for Endo Health Solutions is set to $30. Endo Health's shares closed at $35.96 yesterday.

Analysts at Morgan Stanley downgraded First Horizon National (NYSE: FHN) from “overweight” to “neutral.” The target price for First Horizon National is set to $11. First Horizon National's shares closed at $11.25 yesterday.

Analysts at Piper Jaffray downgraded Vera Bradley (NASDAQ: VRA) from “overweight” to “neutral.” The price target for Vera Bradley has been lowered from $32 to $24. Vera Bradley's shares closed at $22.46 yesterday.

Berenberg downgraded Oracle (NASDAQ: ORCL) from “buy” to “sell.” The target price for Oracle has been lowered from $35 to $28. Oracle's shares closed at $34.12 yesterday.

Latest Ratings for ENDP

DateFirmActionFromTo
Mar 2015Morgan StanleyReinstatesOverweight
Mar 2015Canaccord GenuityMaintainsBuy
Mar 2015Keefe Bruyette & WoodsMaintainsOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ENDP + FHN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content